Literature DB >> 28275139

The Cytokine Response to Lipopolysaccharide Does Not Predict the Host Response to Infection.

Benjamin A Fensterheim1, Yin Guo1, Edward R Sherwood1,2, Julia K Bohannon3.   

Abstract

The magnitude of the LPS-elicited cytokine response is commonly used to assess immune function in critically ill patients. A suppressed response, known as endotoxin tolerance, is associated with worse outcomes, yet endotoxin tolerance-inducing TLR4 ligands are known to protect animals from infection. Thus, it remains unknown whether the magnitude of the LPS-elicited cytokine response provides an accurate assessment of antimicrobial immunity. To address this, the ability of diverse TLR ligands to modify the LPS-elicited cytokine response and resistance to infection were assessed. Priming of mice with LPS, monophosphoryl lipid A (MPLA), or poly(I:C) significantly reduced plasma LPS-elicited proinflammatory cytokines, reflecting endotoxin tolerance, whereas CpG-ODN-primed mice showed augmented cytokine production. In contrast, LPS, MPLA, and CpG-ODN, but not poly(I:C), improved the host response to a Pseudomonas aeruginosa infection. Mice primed with protective TLR ligands, including CpG-ODN, showed reduced plasma cytokines during P. aeruginosa infection. The protection imparted by TLR ligands persisted for up to 15 d yet was independent of the adaptive immune system. In bone marrow-derived macrophages, protective TLR ligands induced a persistent metabolic phenotype characterized by elevated glycolysis and oxidative metabolism as well as augmented size, granularity, phagocytosis, and respiratory burst. Sustained augmentation of glycolysis in TLR-primed cells was dependent, in part, on hypoxia-inducible factor 1-α and was essential for increased phagocytosis. In conclusion, the magnitude of LPS-elicited cytokine production is not indicative of antimicrobial immunity after exposure to TLR ligands. Additionally, protective TLR ligands induce sustained augmentation of phagocyte metabolism and antimicrobial function.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28275139      PMCID: PMC5380530          DOI: 10.4049/jimmunol.1602106

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

Review 1.  The endothelium in sepsis: source of and a target for inflammation.

Authors:  C E Hack; S Zeerleder
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

2.  HIF-1alpha is essential for myeloid cell-mediated inflammation.

Authors:  Thorsten Cramer; Yuji Yamanishi; Björn E Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S Firestein; Hans Peter Gerber; Napoleone Ferrara; Randall S Johnson
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

3.  IRAK-M is a negative regulator of Toll-like receptor signaling.

Authors:  Koichi Kobayashi; Lorraine D Hernandez; Jorge E Galán; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

4.  IFN-γ abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling.

Authors:  Janice Chen; Lionel B Ivashkiv
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

5.  Induction of endotoxin tolerance in vivo inhibits activation of IRAK4 and increases negative regulators IRAK-M, SHIP-1, and A20.

Authors:  Yanbao Xiong; Andrei E Medvedev
Journal:  J Leukoc Biol       Date:  2011-09-20       Impact factor: 4.962

6.  Immunotherapy for sepsis--a new approach against an ancient foe.

Authors:  Richard S Hotchkiss; Steven Opal
Journal:  N Engl J Med       Date:  2010-07-01       Impact factor: 91.245

7.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

Review 8.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

9.  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Authors:  Steven M Opal; Pierre-Francois Laterre; Bruno Francois; Steven P LaRosa; Derek C Angus; Jean-Paul Mira; Xavier Wittebole; Thierry Dugernier; Dominique Perrotin; Mark Tidswell; Luis Jauregui; Kenneth Krell; Jan Pachl; Takeshi Takahashi; Claus Peckelsen; Edward Cordasco; Chia-Sheng Chang; Sandra Oeyen; Naoki Aikawa; Tatsuya Maruyama; Roland Schein; Andre C Kalil; Marc Van Nuffelen; Melvyn Lynn; Daniel P Rossignol; Jogadish Gogate; Mary B Roberts; Janice L Wheeler; Jean-Louis Vincent
Journal:  JAMA       Date:  2013-03-20       Impact factor: 56.272

10.  Enhanced phagocytosis and bactericidal activity of hepatic reticuloendothelial system during endotoxin tolerance.

Authors:  G Ruggiero; A Andreana; R Utili; D Galante
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

View more
  23 in total

Review 1.  Maternal modifiers of the infant gut microbiota: metabolic consequences.

Authors:  Christopher M Mulligan; Jacob E Friedman
Journal:  J Endocrinol       Date:  2017-07-27       Impact factor: 4.286

2.  Monophosphoryl lipid A pretreatment suppresses sepsis- and LPS-induced proinflammatory cytokine production in the medullary thick ascending limb.

Authors:  Bruns A Watts; Esther Tamayo; Edward R Sherwood; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-18

3.  The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism.

Authors:  Benjamin A Fensterheim; Jamey D Young; Liming Luan; Ruby R Kleinbard; Cody L Stothers; Naeem K Patil; Allison G McAtee-Pereira; Yin Guo; Irina Trenary; Antonio Hernandez; Jessica B Fults; David L Williams; Edward R Sherwood; Julia K Bohannon
Journal:  J Immunol       Date:  2018-04-23       Impact factor: 5.422

Review 4.  Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection.

Authors:  Antonio Hernandez; Naeem K Patil; Cody L Stothers; Liming Luan; Margaret A McBride; Allison M Owen; Katherine R Burelbach; David L Williams; Edward R Sherwood; Julia K Bohannon
Journal:  Pharmacol Res       Date:  2019-11-02       Impact factor: 7.658

Review 5.  The biology of natural killer cells during sepsis.

Authors:  Yin Guo; Naeem K Patil; Liming Luan; Julia K Bohannon; Edward R Sherwood
Journal:  Immunology       Date:  2017-11-16       Impact factor: 7.397

Review 6.  Regulation of leukocyte function by citric acid cycle intermediates.

Authors:  Naeem K Patil; Julia K Bohannon; Antonio Hernandez; Tazeen K Patil; Edward R Sherwood
Journal:  J Leukoc Biol       Date:  2019-02-21       Impact factor: 4.962

7.  Monophosphoryl lipid A induces protection against LPS in medullary thick ascending limb through induction of Tollip and negative regulation of IRAK-1.

Authors:  Bruns A Watts; Esther Tamayo; Edward R Sherwood; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

8.  Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens.

Authors:  Antonio Hernandez; Liming Luan; Cody L Stothers; Naeem K Patil; Jessica B Fults; Benjamin A Fensterheim; Yin Guo; Jingbin Wang; Edward R Sherwood; Julia K Bohannon
Journal:  Crit Care Med       Date:  2019-11       Impact factor: 7.598

Review 9.  Hypoxia-inducible factor-1α regulation of myeloid cells.

Authors:  C L Stothers; L Luan; B A Fensterheim; J K Bohannon
Journal:  J Mol Med (Berl)       Date:  2018-11-01       Impact factor: 4.599

10.  Monophosphoryl lipid A prevents impairment of medullary thick ascending limb [Formula: see text] absorption and improves plasma [Formula: see text] concentration in septic mice.

Authors:  Bruns A Watts; Thampi George; Edward R Sherwood; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.